We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Non-Invasive Saliva Test for Early and Accurate Detection of Prostate Cancer Presented at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

A new non-invasive test that uses saliva samples to accurately diagnose cases of prostate cancer was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The test developed by researchers at the Tehran University of Medical Sciences (Tehran, Iran) could allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.

A key challenge in cancer care is the diagnosis of prostate cancer, one of the most common cancers in men. Clinicians currently use invasive biopsies or tests for prostate-specific antigen levels to diagnose prostate cancer in the clinic. But prostate cancer can be hard to spot during the early stages and can be tricky to distinguish from benign prostatic hyperplasia (BPH), a benign enlargement of the prostate that can appear as men age.

In an effort to solve these issues, researchers have developed a new test for prostate cancer that uses saliva samples, which can be collected repeatedly and non-invasively. Their test distinguishes prostate cancer from BPH by testing saliva for eight different microRNAs that either support or suppress tumor growth. The researchers validated their test with saliva samples from 180 men between 45 and 50 years of age, 60 of whom had been diagnosed with prostate cancer using standard methods and 60 of whom had been diagnosed with BPH.

“The advantage of our study is the use of several microRNAs, which have been reported to be detectable in the blood much earlier than the progression of cancer, which makes for a better diagnosis, as well as the use of saliva as a non-invasive biological sample that causes little pain to patients,” said Dr. Jamal Amri of the Tehran University of Medical Sciences.

Related Links:
Tehran University of Medical Sciences 

New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Rheumatoid Arthritis Test
Finecare RF Rapid Quantitative Test
New
Treponema Pallidum Test
ZEUS IFA Fluorescent Treponemal Antibody-Absorption (FTA-ABS) Test System

Print article
ADLM

Channels

Immunology

view channel
Image: New research has revealed a novel biomarker for autoimmune diseases (Photo courtesy of Shutterstock)

Novel Analytical Method Tracks Progression of Autoimmune Diseases

Patients with autoimmune diseases often have lifelong contact with doctors and hospitals. The typical patient diagnosed is a woman in her fifties and the disease requires lifelong treatment.... Read more

Microbiology

view channel
Image: The unique barcoding system enables tracking of K. pneumoniae as it moves throughout the body (Photo courtesy of AdobeStock)

Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream

Bacteremia, also known as blood poisoning, occurs when bacteria manage to overcome the body's immune defenses. This condition can progress into sepsis, a serious illness that is responsible for over a... Read more

Pathology

view channel
Image: The squares are representative partial pictures from the cancer microscopy slides, that the AI system has automatically organized by their similarity (Photo courtesy of University of Jyväskylä)

New AI Tool Outperforms Previous Methods for Identifying Colorectal Cancer from Tissue Sample Analysis

Tissue analysis typically involves a pathologist reviewing scanned digital slides from a patient’s intestinal sample and marking specific areas, such as those where cancerous and related tissues are present.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.